Europe Pharmacogenetics Testing in Psychiatry/Depression Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Pharmacogenetics Testing in Psychiatry/Depression Market Overview

The Europe pharmacogenetics testing in psychiatry/depression market was valued at USD 461.10 million in 2025 and is projected to reach USD 912.04 million by 2033, growing at a CAGR of 8.9% from 2026 to 2033. The market is witnessing steady expansion driven by increasing adoption of precision medicine approaches in mental health care, growing prevalence of depression and other psychiatric disorders, and rising clinical awareness of gene–drug interaction testing to improve antidepressant efficacy and reduce adverse drug reactions.

The increasing burden of treatment-resistant depression across Europe, combined with supportive regulatory frameworks and expanding reimbursement coverage for genetic testing in select countries, is accelerating clinical adoption. Integration of pharmacogenetic testing into psychiatric practice is further supported by advancements in next-generation sequencing, AI-driven decision support tools, and hospital-based personalized medicine programs. Growing use in psychiatric clinics, academic research centers, and specialized mental health institutions is expected to further strengthen market penetration over the forecast period.

Key Market Trends & Insights

• Germany dominated the Europe pharmacogenetics testing in psychiatry/depression market with the largest revenue share of 18.22% in 2025, supported by advanced clinical genomics infrastructure, strong hospital-based adoption of precision psychiatry, and favorable reimbursement pathways for molecular diagnostics.
• The Depression segment led the market with a 45.50% share in 2025, driven by the high prevalence of major depressive disorder and increasing adoption of gene–drug interaction testing to improve antidepressant response.
• The United Kingdom is expected to be the fastest-growing country market at a CAGR of 7.8% from 2026 to 2033, fueled by National Health Service (NHS)-driven genomic medicine programs, expanding mental health screening initiatives, and increasing adoption of personalized psychiatry.
• Bipolar Disorders are the fastest-growing type, projected to register a CAGR of 8.9%, reflecting the surge in recognition of genetic variability in mood stabilizer response and adverse drug reactions.
• The Chromosomal Array-Based Tests segment dominated the test type category with a 55.60% revenue share in 2025, led by its clinical reliability, faster turnaround time, and cost-effectiveness in detecting gene variants linked to psychiatric drug response.
• Adult accounted for 65.70% of the market, preferred by the high prevalence of depression and anxiety disorders in working-age populations.
• The Software & Services segment is the fastest-growing products category, with a CAGR of 9.0%, driven by rising integration of AI-based interpretation tools and clinical decision-support platforms.

Market Size & Forecast

• Global Market Value (2025): USD 461.10 Million
• Expected Market Value (2033): USD 912.04 Million
• Forecast CAGR (2026–2033): 8.9%
• Leading Country in 2025: Germany
• Fastest Growing Country: United Kingdom

Report Scope and Europe Pharmacogenetics Testing in Psychiatry/Depression Market Segmentation

Europe Pharmacogenetics Testing in Psychiatry/Depression Market Trends

Trend: Expansion of Precision Psychiatry and Clinical Genomics Integration

Pharmacogenetics testing is increasingly being incorporated into routine psychiatric care across Europe as clinicians adopt precision medicine approaches to optimize antidepressant and antipsychotic therapies. Hospitals and mental health centers are integrating genetic profiling into treatment planning to reduce trial-and-error prescribing and improve patient outcomes. The growing use of multi-gene panels, coupled with digital decision-support systems, is enhancing clinical workflow efficiency and enabling more individualized treatment strategies. For instance, healthcare systems in countries such as the Netherlands and Germany are embedding pharmacogenomic tools into psychiatric prescribing guidelines for depression management.

Europe Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics

Key Market Driver: Rising Burden of Treatment-Resistant Depression and Personalized Therapy Demand

The increasing prevalence of treatment-resistant depression across Europe is significantly driving demand for pharmacogenetic testing to improve drug response prediction and reduce adverse drug reactions. Clinicians are increasingly relying on gene–drug interaction data to select effective antidepressants earlier in the treatment pathway, thereby improving recovery rates and reducing healthcare costs. Support from national genomic medicine initiatives and expanding awareness among psychiatrists is further accelerating adoption across hospitals and specialty clinics. For instance, the United Kingdom’s NHS Genomic Medicine Service is actively supporting the use of pharmacogenomic testing in psychiatric care pathways for depression treatment optimization.

Key Restraint/Challenge: Limited Standardization and High Testing Costs

A major restraint in the Europe pharmacogenetics testing in psychiatry/depression market is the lack of standardized clinical guidelines across countries and the relatively high cost of multi-gene testing panels. Variability in reimbursement policies and limited insurance coverage in several European healthcare systems restrict widespread adoption, particularly in smaller psychiatric clinics and outpatient settings. Additionally, the need for specialized laboratory infrastructure and trained personnel increases operational complexity and limits scalability in certain regions.

For instance, in several Southern and Eastern European countries, adoption remains limited due to fragmented reimbursement frameworks and uneven access to advanced molecular diagnostic facilities.

Key Market Opportunity: Expansion of AI-Driven Clinical Decision Support and Digital Psychiatry Platforms

The integration of artificial intelligence with pharmacogenetic data presents a major growth opportunity by enabling real-time, data-driven antidepressant selection and personalized treatment optimization. AI-powered platforms can analyze genetic markers alongside clinical and behavioral data to improve prescribing accuracy and reduce adverse drug reactions. The growing adoption of cloud-based genomic databases and digital psychiatry tools is expected to further enhance accessibility and scalability of testing services across Europe. For instance, emerging digital health platforms in countries such as France and Sweden are deploying AI-enabled pharmacogenomic interpretation tools to support psychiatrists in treatment planning for depression and anxiety disorders.

Europe Pharmacogenetics Testing in Psychiatry/Depression Market Scope

The Europe pharmacogenetics testing in psychiatry/depression market is segmented on the basis of type, test type, patient type, gene type, products, end user, and distribution channel.

• By Type

On the basis of type of disorder, the Europe pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders. The Depression segment dominated the market with a 45.50% share in 2025, owing to the high prevalence of major depressive disorder and increasing adoption of gene–drug interaction testing to improve antidepressant response. Clinicians across Europe are increasingly using pharmacogenetic insights to reduce trial-and-error prescribing in depression treatment. Strong clinical focus on treatment-resistant depression is further reinforcing demand. Expanding psychiatric healthcare infrastructure and growing awareness of personalized medicine are supporting segment dominance. For instance, hospitals in Germany and the UK are integrating pharmacogenomic testing into depression treatment pathways. The segment continues to benefit from rising mental health burden and improved diagnostic accessibility.

The Bipolar Disorders segment is expected to witness the fastest growth at a CAGR of 8.9% from 2026 to 2033, driven by increasing recognition of genetic variability in mood stabilizer response and adverse drug reactions. Pharmacogenetic testing is being increasingly used to guide lithium and anticonvulsant therapy selection in bipolar patients. Growing psychiatric research in personalized treatment approaches is accelerating clinical adoption. Expanding use in specialty mental health centers and academic hospitals is further supporting growth. Improved reimbursement frameworks in select European countries are also enhancing accessibility. For instance, France and the Netherlands are expanding pharmacogenomic-guided bipolar disorder treatment studies.

• By Test Type

On the basis of test type, the Europe pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing and chromosomal array-based tests. The Chromosomal Array-Based Tests segment dominated the market with a 55.60% share in 2025, driven by its clinical reliability, faster turnaround time, and cost-effectiveness in detecting gene variants linked to psychiatric drug response. These tests are widely used in hospital laboratories and diagnostic centers for routine pharmacogenetic screening. Established clinical validation and regulatory acceptance across Europe further support their widespread adoption. Integration into psychiatric prescribing workflows is increasing across public healthcare systems. For instance, clinical laboratories in the UK and Germany routinely use array-based panels for antidepressant response prediction. The segment remains the backbone of clinical pharmacogenetic diagnostics.

The Whole Genome Sequencing segment is expected to witness the fastest growth at a CAGR of 9.1% from 2026 to 2033, driven by increasing demand for comprehensive genetic profiling in complex psychiatric conditions. WGS enables identification of rare and novel variants associated with drug response and treatment resistance. Declining sequencing costs and advances in bioinformatics are making it more clinically feasible. Growing research initiatives in precision psychiatry are further accelerating adoption. Hospitals and academic institutes are increasingly using WGS for refractory depression and multi-drug resistance cases. For instance, research hospitals in Sweden and France are expanding genome-wide psychiatric studies.

• By Patient Type

On the basis of patient type, the market is segmented into child, adult, and geriatric populations. The Adult segment dominated the market with a 65.70% share in 2025, primarily due to the high prevalence of depression and anxiety disorders in working-age populations. Adults represent the largest group undergoing antidepressant and antipsychotic therapies, making them the primary target for pharmacogenetic testing. Increased awareness of mental health and early diagnosis programs is further driving testing rates. Integration of pharmacogenomics into outpatient psychiatric care is expanding across Europe. For instance, Germany and the UK report high adoption among adult psychiatric outpatient services. The segment benefits from strong clinical demand and insurance coverage support.

The Geriatric segment is expected to witness the fastest growth at a CAGR of 8% from 2026 to 2033, driven by rising mental health disorders among the aging population and higher risk of adverse drug reactions. Elderly patients often take multiple medications, increasing the need for personalized drug optimization. Pharmacogenetic testing is increasingly used to reduce polypharmacy risks and improve treatment safety. Expanding elderly care infrastructure and mental health screening programs are supporting adoption. Healthcare systems across Italy and Spain are increasingly focusing on geriatric psychiatry optimization. For instance, hospital networks in Italy are integrating pharmacogenomic testing for elderly depression management.

• By Gene Type

On the basis of gene type, the market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others. The CYP2D6 segment dominated the market with a 25.30% share in 2025, owing to its critical role in metabolizing commonly prescribed antidepressants and antipsychotics. Variations in CYP2D6 significantly influence drug efficacy and adverse reaction risk, making it a key biomarker in psychiatric pharmacogenetics. It is widely included in commercial testing panels across Europe. Clinical guidelines increasingly recommend CYP2D6 testing before initiating psychiatric medications. For instance, Germany and the Netherlands routinely include CYP2D6 analysis in psychiatric pharmacogenomic workflows. The segment remains central to treatment personalization strategies.

The HTR2A/C segment is expected to witness the fastest growth at a CAGR of 8.9% from 2026 to 2033, driven by increasing research on serotonin receptor gene variants and antidepressant response variability. These genes are strongly associated with SSRI efficacy and side-effect profiles. Expanding clinical validation studies are supporting their inclusion in advanced testing panels. Growing adoption of multi-gene psychiatric panels is further accelerating usage. Research hospitals in France and Sweden are actively integrating serotonin pathway gene analysis into depression treatment studies. For instance, HTR2A/C-based testing is increasingly used in SSRIs response prediction programs.

• By Products

On the basis of products, the market is segmented into instruments, consumables, and software & services. The Consumables segment dominated the market with a 50.55% share in 2025, driven by continuous demand for test kits, reagents, and assay panels used in routine pharmacogenetic testing. High testing volumes across hospitals and diagnostic laboratories ensure recurring revenue generation. Standardized consumable kits simplify laboratory workflows and improve testing consistency. Increasing adoption of panel-based testing is further supporting segment growth. For instance, laboratories in Germany and France rely heavily on pre-packaged consumable kits for psychiatric pharmacogenetics. The segment benefits from repeat usage and scalable deployment.

The Software & Services segment is expected to witness the fastest growth at a CAGR of 9.1% from 2026 to 2033, driven by rising integration of AI-based interpretation tools and clinical decision-support platforms. These systems help clinicians translate genetic data into actionable psychiatric treatment recommendations. Cloud-based genomic analytics platforms are expanding accessibility across healthcare networks. Increasing digitalization of psychiatric care is further accelerating adoption. For instance, hospitals in the UK and Sweden are implementing AI-driven pharmacogenomic interpretation systems for depression treatment planning.

• By End User

On the basis of end user, the market is segmented into hospitals and clinics, diagnostic laboratories, academic and research institutes, and others. The Hospitals and Clinics segment dominated the market with a 55.60% share in 2025, due to integrated psychiatric care delivery and higher patient inflow requiring antidepressant therapy optimization. These institutions are primary adopters of pharmacogenetic testing for routine clinical decision-making. Availability of trained psychiatrists and molecular diagnostic capabilities supports dominance. Increasing incorporation of genomic medicine into hospital psychiatry departments is further strengthening usage. For instance, Germany and the UK hospitals are actively using pharmacogenetic testing in mental health treatment pathways. The segment benefits from structured reimbursement systems and established clinical workflows.

The Academic and Research Institutes segment is expected to witness the fastest growth at a CAGR of 8.9% from 2026 to 2033, driven by expanding research in precision psychiatry and gene–drug interaction studies. These institutes are leading innovation in biomarker discovery and multi-gene panel development. Increasing government and EU funding for mental health genomics is supporting growth. Collaborative studies between universities and healthcare providers are accelerating clinical validation. For instance, research institutions in France and Sweden are conducting large-scale pharmacogenomic studies in depression and bipolar disorder.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, third party distribution, hospital pharmacy, and others. The Direct Tender segment dominated the market with a 45.50% share in 2025, driven by large-scale procurement by public hospitals, national healthcare systems, and diagnostic networks. Direct contracts ensure cost efficiency and standardized supply of pharmacogenetic testing kits and services. Government-led genomic medicine programs further strengthen this procurement model. Centralized purchasing improves scalability and quality control. For instance, the UK NHS and German hospital systems frequently use direct tender procurement for diagnostic services. The segment benefits from structured public healthcare frameworks.

The Third Party Distribution segment is expected to witness the fastest growth at a CAGR of 8.9% from 2026 to 2033, driven by expanding private laboratory networks and increasing demand from decentralized psychiatric clinics. Distribution partners help improve accessibility of testing services across smaller healthcare facilities. Growing privatization of diagnostic services is further supporting adoption. Logistics efficiency and wider geographic reach are key advantages of this model. For instance, private diagnostic networks in Italy and Spain are increasingly relying on third-party distributors for pharmacogenetic test kits.

Europe Pharmacogenetics Testing in Psychiatry/Depression Market Regional Analysis

Germany dominated the Europe pharmacogenetics testing in psychiatry/depression market with the largest revenue share of 18.22% in 2025, supported by advanced clinical genomics infrastructure, strong hospital-based adoption of precision psychiatry, and favorable reimbursement pathways for molecular diagnostics. The country benefits from well-established reimbursement frameworks for genetic testing in select clinical applications and strong investment in personalized healthcare initiatives. Increasing prevalence of depression and growing use of antidepressants are driving demand for gene–drug interaction testing to improve treatment outcomes and reduce adverse drug reactions. Expanding collaboration between academic research institutes and healthcare providers is further accelerating clinical adoption. Rising implementation of pharmacogenomic-guided prescribing in hospitals and specialty psychiatric clinics continues to strengthen Germany’s leading position in the European market.

The Germany Pharmacogenetics Testing in Psychiatry/Depression Market Insight

The Germany pharmacogenetics testing in psychiatry/depression market is witnessing strong growth due to advanced clinical genomics infrastructure, high adoption of precision medicine in psychiatric care, and increasing use of gene–drug interaction testing for antidepressant optimization. Hospitals and specialty psychiatric clinics are integrating pharmacogenetic panels into routine treatment planning to improve drug efficacy and reduce adverse reactions. The country’s strong reimbursement support for molecular diagnostics and active participation in EU genomic medicine initiatives further strengthen adoption. In addition, rising prevalence of depression and treatment-resistant cases is accelerating demand for personalized psychiatric care solutions across Germany.

U.K. Pharmacogenetics Testing in Psychiatry/Depression Market Insight

The U.K. pharmacogenetics testing in psychiatry/depression market is experiencing steady expansion driven by NHS-led genomic medicine programs, growing adoption of personalized psychiatry, and increasing use of pharmacogenomic-guided antidepressant prescribing. Integration of genetic testing into mental health care pathways is improving treatment outcomes and reducing trial-and-error prescribing in clinical practice. The presence of structured national healthcare systems and expanding digital health infrastructure is further supporting adoption. In addition, increasing focus on treatment-resistant depression and adverse drug reaction reduction continues to strengthen market growth across the U.K.

France Pharmacogenetics Testing in Psychiatry/Depression Market Insight

The France pharmacogenetics testing in psychiatry/depression market is growing steadily due to increasing investment in national genomics programs, rising awareness of precision psychiatry, and expanding use of pharmacogenetic testing in psychiatric treatment optimization. Hospitals and specialty mental health centers are gradually adopting multi-gene testing panels to improve antidepressant selection and reduce side effects. Strong public healthcare support and increasing research activity in psychiatric genomics are further driving adoption. In addition, growing collaboration between academic institutes and healthcare providers is enhancing clinical implementation across France.

Italy Pharmacogenetics Testing in Psychiatry/Depression Market Insight

The Italy pharmacogenetics testing in psychiatry/depression market is expanding steadily due to increasing mental health burden, growing adoption of personalized medicine approaches, and rising use of genetic testing in hospital-based psychiatric care. Pharmacogenetic testing is increasingly being used to optimize antidepressant therapy and reduce adverse drug reactions, particularly in complex and elderly patient populations. Expanding research activity in clinical genomics and gradual improvement in reimbursement frameworks are supporting adoption. In addition, growing integration of molecular diagnostics in public hospitals is further strengthening market penetration across Italy.

Europe Pharmacogenetics Testing in Psychiatry/Depression Market Share

The Europe pharmacogenetics testing in psychiatry/depression industry is primarily led by well-established companies, including:

• Myriad Genetics, Inc. (U.S.)
• Genomind, Inc. (U.S.)
• OneOme, LLC (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Hoffmann-La Roche Ltd (Switzerland)
• QIAGEN (Netherlands)
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• BGI Genomics Co., Ltd. (China)
• NalaGenetics Pte. Ltd. (Singapore)
• SOPHiA GENETICS SA (Switzerland)
• GenXys Health Care Systems Inc. (Canada)
• ADmera Health LLC (U.S.)
• Labcorp (U.S.)
• Eurofins Scientific SE (Luxembourg)
• Exact Sciences Corporation (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Pacific Edge Ltd (New Zealand)
• Fulgent Genetics, Inc. (U.S.)

Latest Developments in Europe Pharmacogenetics Testing in Psychiatry/Depression Market

• In May 2025, European academic and clinical research networks under EU-funded precision medicine programs continued expanding psychiatric pharmacogenomics studies, focusing on treatment-resistant depression and antidepressant response variability using multi-gene panels and clinical decision-support systems in hospital settings across Germany, France, and the Netherlands
• In June 2024, the Dutch Pharmacogenetics Working Group (DPWG) under the Royal Dutch Pharmacists Association (KNMP) expanded and updated multiple gene–drug guidelines, including psychiatric medications such as antidepressants and antipsychotics, to improve personalized prescribing decisions in clinical practice. These updates strengthened the integration of pharmacogenetic recommendations into routine psychiatric care across the Netherlands and other European healthcare systems adopting DPWG standards
• In March 2023, NHS England advanced its Genomic Medicine Service implementation strategy, expanding the use of pharmacogenomic testing within clinical care pathways, including mental health treatment optimization programs aimed at improving antidepressant response and reducing adverse drug reactions. This initiative supports broader adoption of precision psychiatry across NHS hospitals
• In October 2022, the European Commission strengthened the “1+ Million Genomes (1+MG)” initiative, promoting cross-border genomic data sharing to support personalized medicine applications, including psychiatric genomics research and pharmacogenetic testing development across EU member states
• In September 2021, the European Medicines Agency (EMA) continued to expand regulatory guidance discussions on the use of pharmacogenomic data in drug development and personalized medicine, supporting improved safety and efficacy frameworks relevant to psychiatric drug prescribing across Europe

SKU-60337